NCT07762885 Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 636 participants in total. It began in 2026-07-01 with a primary completion date of 2031-06.

Brief Summary

This is a prospective, multicenter, randomized, open-label, phase III non-inferiority trial designed to evaluate whether omission of postoperative radiotherapy is clinically acceptable in patients with low- and intermediate-risk ductal carcinoma in situ (DCIS) following breast-conserving surgery. Eligible patients include women aged ≥40 years with ER-positive, low- or intermediate-grade DCIS, tumor size ≤2.5 cm, negative surgical margins ≥3 mm, absence of comedo necrosis, and screen-detected unifocal disease. Patients will be randomized to postoperative observation alone or adjuvant radiotherapy. The primary endpoint is 5-year ipsilateral breast tumor recurrence (IBTR).

Eligibility Criteria

Inclusion Criteria: 1. Female patients aged ≥40 years； 2. Histologically confirmed low- or intermediate-grade ductal carcinoma in situ (DCIS) without invasive carcinoma, including incidental DCIS identified within benign breast lesions； 3. Tumor size ≤2.5 cm on final pathology； 4. Negative surgical margins ≥3 mm, including margins obtained after re-excision； 5. Estrogen receptor-positive disease (ER ≥10%) with planned endocrine therapy using tamoxifen； 6. Unifocal lesion； 7. Absence of comedo necrosis； 8. Screen-detected disease without bloody nipple discharge or palpable mass； 9. Clinically node-negative disease； 10. Patients randomized to the radiotherapy arm must initiate radiotherapy within 3 months after surgery； 11. Central pathology review by the participating institution required； 12. Ability to understand and willingness to sign written informed consent. Exclusion Criteria: 1. Known BRCA1 or BRCA2 germline mutation carriers (genetic testing not mandatory)； 2. Contraindications to radiotherapy, including active connective tissue disease； 3. Active infection requiring systemic treatment； 4. Bilateral breast cancer or prior contralateral breast cancer； 5. Severe uncontrolled comorbidities, including significant cardiac, pulmonary, hepatic, renal, hematologic, or psychiatric disorders； 6. History of other malignancies, including thyroid cancer, except adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ； 7. Prior thoracic radiotherapy； 8. Pregnant or breastfeeding patients； 9. Estimated life expectancy ≤5 years； 10. Poor compliance or inability to adhere to study follow-up requirements.

Contact & Investigator

Frequently Asked Questions

Related Trials